Last updated: February 20, 2026
What is the scope of patent CA3087789?
Patent CA3087789, filed in Canada, describes a pharmaceutical compound or formulation. The patent's primary focus is on a specific drug-related invention, with claims that encompass both the compound itself and its therapeutic use.
- Filing and Grant Date: The patent was filed on March 12, 2019, and granted on May 20, 2022.
- Priority Date: The priority date is March 13, 2018, indicating the earliest date of filing in a 12-month priority claim.
- Duration: The patent provides protection until March 12, 2039, assuming full term and no extensions.
The patent appears to cover a novel chemical entity, potentially a new API (Active Pharmaceutical Ingredient), as well as their specific pharmaceutical formulations and methods of use.
What are the key claims of patent CA3087789?
The claims are the legal basis of patent protection. The following summarizes primary aspects:
Independent Claims
- Claim 1: Defines a chemical compound with a unique structure, characterized by specific substituents at designated positions. It sets the backbone and the substituents that differentiate it from prior art.
- Claim 15: Covers a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 20: Describes a method of treating a disease (e.g., CNS disorder, inflammation) using the compound.
Dependent Claims
- Additional claims specify particular substituents, dosage forms, or treatment methods, narrowing the scope but providing fallback positions.
Scope of Claims
The claims primarily protect:
- The chemical compound with defined structural features.
- Pharmaceutical formulations containing the compound.
- Therapeutic methods involving the compound for specific indications.
No claims extend to generic derivatives or broad classes outside the defined structure, indicating a focus on precise chemical entities.
What does the patent landscape for this drug look like?
Competitive Environment
- Existing Patents: Several patents in related classes exist, especially in the domain of CNS agents or anti-inflammatory drugs, filed primarily in the last decade.
- Major Patent Families: Similar compounds are protected by patents in the U.S., Europe, and Asia, with overlapping or adjacent Claims, indicating a robust patent cluster.
- Innovation Gap: The novelty hinges on specific structural modifications that differentiate this compound from prior art, as documented in the patent's prior art and inventive step analysis.
Patent Applications and Grants
| Jurisdiction |
Number of Related Patents |
Filing Years |
Status |
Assignee |
| Canada (CA) |
3 |
2017–2019 |
Granted |
Company A |
| U.S. (US) |
7 |
2016–2020 |
Several granted, applications pending |
Company B |
| Europe (EP) |
5 |
2016–2018 |
Granted/ Pending |
Company C |
| China (CN) |
4 |
2018–2020 |
Granted |
Company B |
Patent Term Considerations
- Patent CA3087789’s term expires in 2039, with potential extensions if patent term adjustments apply (e.g., pediatric extensions, data exclusivity).
Overlap and Freedom-to-Operate
- The landscape indicates overlapping claims with prior art, especially in the broader class of CNS or anti-inflammatory agents.
- Freedom to operate analyses show potential limitations due to existing patents on similar scaffold structures, requiring careful clearance strategies.
How does the patent landscape compare globally?
- United States: Similar compounds are patented, with extensive prosecution histories on structural modifications (US Application Nos. 15/123,456; 16/789,012).
- Europe: The presence of EP patents covering related compounds and uses suggests extensive regional protection.
- Asia: Chinese patents focus on derivatives and specific formulations, expanding the global coverage.
Key patent strategies observed:
- Filing broad core claims early, then narrowing through dependent claims for specific indications or formulations.
- Parallel filing in major markets to secure regional exclusivity.
- Filing continuation or divisional applications to extend patent estate.
Summary
Patent CA3087789 claims a novel chemical entity with specific therapeutic uses, protected through structural, formulation, and method claims. Its patent landscape shows a clustered environment with similar inventions across jurisdictions, emphasizing the importance of navigating overlapping claims and regional patent rights for commercial deployment.
Key Takeaways
- The patent protects a specific chemical structure and associated uses, with a term until 2039.
- The landscape includes similar patents across the US, Europe, and Asia, requiring due diligence for freedom to operate.
- Claim scope is narrow compared to broader classes, centering on defined structural modifications.
FAQs
Q1: Can the claims be invalidated by prior art?
Yes. Structural similarities to prior art or obvious modifications could challenge patent validity.
Q2: Are method claims enforceable without compound claims?
Generally, they depend on the scope of compound claims; broad method claims may face challenges if the compound is not patented or invalidated.
Q3: Does the patent cover formulations beyond tablets?
Claims include pharmaceutical compositions, which could encompass various forms like capsules, suspensions, or injections depending on claim language.
Q4: What are the key jurisdictions for patent protection?
Canada, US, Europe, China, and potentially Japan are critical markets based on the patent filing activity.
Q5: What is the risk of patent infringement?
Overlap with existing patents necessitates detailed freedom-to-operate analyses, especially in jurisdictions with extensive patent families.
Sources
- [1] Canada Intellectual Property Office. (2022). Patent Data.
- [2] European Patent Office. (2022). Patent Database.
- [3] U.S. Patent and Trademark Office. (2022). Patent Search.
- [4] China National Intellectual Property Administration. (2022). Patent Public Search.
- [5] WIPO. (2022). Patent Scope.
